Cypress Capital Management LLC Has $4.86 Million Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Cypress Capital Management LLC lifted its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 3.5% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 37,568 shares of the company’s stock after purchasing an additional 1,257 shares during the quarter. Cypress Capital Management LLC’s holdings in Johnson & Johnson were worth $4,861,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. Virtus ETF Advisers LLC bought a new stake in shares of Johnson & Johnson during the 2nd quarter worth $25,000. Krane Funds Advisors LLC bought a new stake in shares of Johnson & Johnson during the 2nd quarter worth $26,000. Financial Advantage Inc. bought a new stake in shares of Johnson & Johnson during the 3rd quarter worth $28,000. Crewe Advisors LLC boosted its holdings in Johnson & Johnson by 725.9% in the 2nd quarter. Crewe Advisors LLC now owns 223 shares of the company’s stock valued at $31,000 after purchasing an additional 196 shares during the period. Finally, Eii Capital Management Inc. bought a new stake in Johnson & Johnson in the 3rd quarter valued at $39,000. Institutional investors own 72.25% of the company’s stock.

JNJ opened at $133.00 on Friday. The company has a current ratio of 1.26, a quick ratio of 1.00 and a debt-to-equity ratio of 0.46. The stock has a market capitalization of $343.25 billion, a PE ratio of 16.26, a PEG ratio of 2.20 and a beta of 0.69. Johnson & Johnson has a 1-year low of $121.00 and a 1-year high of $148.99. The firm has a 50-day moving average price of $130.83 and a two-hundred day moving average price of $134.05.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, October 15th. The company reported $2.12 earnings per share for the quarter, beating the consensus estimate of $2.00 by $0.12. The firm had revenue of $20.73 billion during the quarter, compared to analysts’ expectations of $20.14 billion. Johnson & Johnson had a net margin of 21.09% and a return on equity of 39.81%. The company’s quarterly revenue was up 1.9% compared to the same quarter last year. During the same quarter last year, the company posted $2.05 EPS. On average, research analysts predict that Johnson & Johnson will post 8.65 EPS for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Tuesday, November 26th will be given a $0.95 dividend. This represents a $3.80 annualized dividend and a yield of 2.86%. The ex-dividend date is Monday, November 25th. Johnson & Johnson’s payout ratio is presently 46.45%.

A number of equities analysts have recently commented on JNJ shares. Sanford C. Bernstein raised shares of Johnson & Johnson from a “market perform” rating to an “outperform” rating and set a $155.00 price objective for the company in a report on Friday, October 11th. Atlantic Securities upgraded shares of Johnson & Johnson from an “underweight” rating to a “neutral” rating in a research report on Wednesday, October 16th. Zacks Investment Research upgraded shares of Johnson & Johnson from a “sell” rating to a “hold” rating and set a $142.00 target price for the company in a research report on Thursday, October 17th. Goldman Sachs Group set a $169.00 target price on shares of Johnson & Johnson and gave the stock a “buy” rating in a research report on Tuesday, August 27th. Finally, Bank of America reiterated a “hold” rating and set a $150.00 target price on shares of Johnson & Johnson in a research report on Tuesday, July 16th. Six equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. Johnson & Johnson presently has an average rating of “Buy” and an average target price of $151.64.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Recommended Story: Inverted Yield Curve

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply